Podcast
Questions and Answers
What is a key concern for gene therapy treatment in Denmark?
What is a key concern for gene therapy treatment in Denmark?
- Affordability issues arising from individual hospitals being responsible for delivering specialist treatment (correct)
- Lack of availability of gene therapy treatment in Denmark
- Lack of network of specialist centers for gene therapy treatment
- Government regulations restricting gene therapy treatment
Who is responsible for covering the treatment costs for gene therapy and ATMPs in Denmark?
Who is responsible for covering the treatment costs for gene therapy and ATMPs in Denmark?
- Patients themselves
- Pharmaceutical companies
- Hospitals and health insurers (correct)
- The government
What approach has Denmark taken to handle equity concerns for gene therapy treatment?
What approach has Denmark taken to handle equity concerns for gene therapy treatment?
- Limiting access to gene therapy treatment based on regions
- Relying solely on government funding for gene therapy treatment
- Privatizing gene therapy treatment centers
- Built-in service preparation requirements in a joint horizon scanning process at the Nordic level (correct)
What is the current status of market authorization for Fidanacogene elaparvovec in Denmark?
What is the current status of market authorization for Fidanacogene elaparvovec in Denmark?
What burden will be felt by a small number of centers in Denmark in relation to gene therapy treatment?
What burden will be felt by a small number of centers in Denmark in relation to gene therapy treatment?
What are the affordability issues specific to gene therapy and ATMPs in Denmark?
What are the affordability issues specific to gene therapy and ATMPs in Denmark?
What network does Denmark have to treat patients with ATMPs?
What network does Denmark have to treat patients with ATMPs?
How has Denmark addressed equity concerns for gene therapy treatment?
How has Denmark addressed equity concerns for gene therapy treatment?
What is a key challenge faced by a small number of centers in Denmark in relation to gene therapy treatment?
What is a key challenge faced by a small number of centers in Denmark in relation to gene therapy treatment?
What is the current status of market authorization for Fidanacogene elaparvovec in Denmark?
What is the current status of market authorization for Fidanacogene elaparvovec in Denmark?
